The EMMA Consortium, comprised of Nura Health, Lasa Health, and Dama Health, was created to accelerate innovation in endometriosis care. Our vision is to revolutionize early, non-invasive diagnosis of endometriosis paired with effective personalized treatment, in order to help solve a debilitating chronic condition impacting more than 1 in 10 women worldwide.



The EMMA Consortium, supported by funding from the Advanced Research Projects Agency for Health (ARPA-H), are pioneering a novel solution for endometriosis, combining genetic, clinical, and biomarker data to eliminate delayed diagnosis and ineffective treatments. Our comprehensive precision medicine platform, the Endometriosis Multimodal Management Application (EMMA), accelerates the early diagnosis and personalized treatment of endometriosis by:

* Developing a non-invasive diagnostic test for endometriosis

* Identifying phenotype-driven genetic & biological markers that influence treatment response

* Improve treatment matching for existing and new therapies



We have launched an IRB-approved clinical study, the EMMA study, for women aged 18-50 years old with or without a clinical diagnosis of endometriosis. To learn more and check your eligibility, please visit https://www.lasahealth.com/emma





The EMMA Consortium

----------------------

Nura Health

www.getnura.com

----------------------

Lasa Health

www.lasahealth.com

----------------------

Dama Health

www.damahealth.com

----------------------